(Q34509642)

2 August 2017

1 reference

title

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Tonini M

1

1 reference

2 August 2017

Vigneri S

series ordinal

2

1 reference

2 August 2017

Savarino V

series ordinal

3

1 reference

2 August 2017

Scarpignato C

series ordinal

4

1 reference

2 August 2017

publication date

1 October 2001

1 reference

Digestive and Liver Disease

2 August 2017

published in

1 reference

2 August 2017

volume

33

1 reference

2 August 2017

issue

7

1 reference

2 August 2017

page(s)

600-606

1 reference

Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

1 reference

7 January 2021

The pharmacology of the gastric acid pump: the H+,K+ ATPase

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Structural aspects of the gastric H,K ATPase

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

1 reference

7 January 2021

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

1 reference

7 January 2021

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Asymmetric synthesis of esomeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Sponsored congress attendance--does it happen, does it matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Pharmacokinetic study of esomeprazole in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980115-8

7 January 2021

10.1016/S1590-8658(01)80115-8

Identifiers

DOI

1 reference

2 August 2017

1 reference